Paper Details

  1. Home
  2. Paper Details

Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.

Author: Cercós LletiAna Cristina, Climente MartíMónica, Cortell FusterClara, Martínez GómezMaría Amparo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Topical rapamycin is effective and safe for the treatment of facial angiofibromas in tuberous sclerosis. Multiple studies demonstrated its efficacy, with the exception of 5 patients in one study. Long-term studies are needed to establish an evidence-based therapeutic protocol.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: facial angiofibromas of tuberous sclerosis are the most prevalent cutaneous manifestation, affecting 80% of patients, which cause facial lesions with negative psychosocial consequences. Newly, topical rapamycin has been established as an effective and safe therapy for this skin conditi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09546634.2021.1905768

データ提供：米国国立医学図書館（NLM）

Topical Rapamycin: A Promising Treatment for Facial Angiofibromas in Tuberous Sclerosis

The field of [tuberous sclerosis complex (TSC) treatment] is constantly seeking effective therapies for the various manifestations of this rare genetic disorder. This systematic review aimed to assess the effectiveness and safety of topical rapamycin in treating facial angiofibromas, a common cutaneous manifestation of TSC. The authors conducted a comprehensive analysis of available scientific evidence, including randomized clinical trials, case series, and single case reports.

Topical Rapamycin: A New Hope for Facial Angiofibromas

The systematic review revealed that topical rapamycin demonstrated significant efficacy in reducing the size and severity of facial angiofibromas in patients with TSC. Moreover, it was generally well-tolerated, with minimal side effects. These findings suggest that topical rapamycin could be a valuable therapeutic option for treating this challenging condition.

Managing Facial Angiofibromas: A Multifaceted Approach

This research emphasizes the importance of considering topical rapamycin as a potential treatment option for facial angiofibromas in TSC. However, further long-term studies are needed to establish a standardized therapeutic protocol and optimize its efficacy.

Dr.Camel's Conclusion

This systematic review is like a treasure map leading us to a potential solution for facial angiofibromas in TSC. It highlights the efficacy and safety of topical rapamycin, offering a glimmer of hope for individuals struggling with this condition.

Date :
  1. Date Completed 2022-07-11
  2. Date Revised 2022-07-11
Further Info :

Pubmed ID

33821748

DOI: Digital Object Identifier

10.1080/09546634.2021.1905768

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.